AADI VS CDXC Stock Comparison

PerformanceTechnicalsEarningsProfitVolatilityAnalyst Price TargetsSentiment
PerformanceTechnicalsEarningsProfitVolatilityAnalyst Price TargetsSentiment

Performance

AADI
10/100

AADI returned -64.24% in the last 12 months. Based on SPY's performance of -13.86%, its performance is below average giving it a score of 10 of 100.

CDXC
10/100

CDXC returned -23.46% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

AADI
57/100

AADI receives a 57 of 100 based on 14 indicators. 7 are bullish, 5 are bearish.

CDXC
10/100

CDXC receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Earnings

AADI
10/100

AADI has missed earnings 9 times in the last 20 quarters.

CDXC
10/100

CDXC has missed earnings 6 times in the last 20 quarters.

Profit

AADI
13/100

Out of the last 20 quarters, AADI has had 2 profitable quarters and has increased their profits year over year on 2 of them.

CDXC
10/100

Out of the last 20 quarters, CDXC has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

AADI
39/100

AADI has had a lower than average amount of volatility over the last 12 months giving it a score of 39 of 100.

CDXC
46/100

CDXC has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

Analyst Price Targets

AADI

"Analyst Price Targets" not found for AADI

CDXC
88/100

2 analysts offer 12-month price targets for CDXC. Together, they have an average target of 0, the most optimistic target put CDXC at 0 within 12-months and the most pessimistic has CDXC at 0.

Sentiment

AADI

"Sentiment" not found for AADI

CDXC
73/100

CDXC had a bullish sentiment score of 72.97% across Twitter and StockTwits over the last 12 months. It had an average of 2.80 posts, 1.24 comments, and 2.68 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

Aadi Bioscience, Inc. Common Stock Summary

Nasdaq / AADI
Healthcare
Biotechnology
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

ChromaDex Corporation Summary

Nasdaq / CDXC
Healthcare
Biotechnology
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.